# Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

> **NCT02427620** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 131 (estimated)

## Conditions studied

- Blastoid Variant Mantle Cell Lymphoma
- Mantle Cell Lymphoma
- Pleomorphic Variant Mantle Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02427620
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06-03
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 131 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02427620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02427620, "Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02427620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*